Drug Trial Radar · NCT07948733
First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That Have Returned or Not Responded to Treatment
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Oct 26, 2026
Primary completion
Sep 14, 2028
Study completion Sep 14, 2028
Sponsor
- Lead sponsor
- Cellogen Therapeutics Pvt. Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Christian Medical College, Vellore, India
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
XenCART is an autologous bispecific CD20 and CD19 CAR T cell product from Cellogen Therapeutics Pvt Ltd. This first in human Phase I study at CMC Vellore will evaluate its safety tolerability and preliminary efficacy in adults with relapsed or refractory CD19 and CD20 positive B cell malignancies including B NHL and B ALL. Patients will undergo leukapheresis 9 to 12 day manufacturing fludarabine and cyclophosphamide lymphodepletion and a single intravenous infusion. The study includes a 28 day DLT evaluation period 24 months of active follow up and long term follow up thereafter. A 3 plus 3 dose escalation design with DSMB review after each cohort will evaluate sequential dose levels of 1 2 and 4 x 10 to the power 6 CAR T cells per kg to determine the recommended Phase II dose. Dual antigen targeting is expected to reduce CD19 negative relapse which is a major limitation of single target CAR T therapy. The study will establish the safety profile of XenCART and support its further development in India.
Conditions
- B-Cell Non-Hodgkin Lymphoma (NHL)
- B-cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions
Autologous bispecific CD20/CD19 CAR-T cells - 1 × 10⁶ cells/kgBiological
All patients receive lymphodepletion with cyclophosphamide 40 mg/kg IV on Day -5 and fludarabine 30 mg/m²/day IV from Day -5 to Day -2, followed by a single IV infusion of autologous bispecific CD20/CD19 CAR-T cells (XenCART; bicartigenlecleucel) at a dose of 1 × 10⁶ CAR-T cells/kg on Day 0. Dose may vary by ±20% due to manufacturing constraints.
Autologous bispecific CD20/CD19 CAR-T cells - 2 × 10⁶ cells/kgBiological
All patients receive lymphodepletion with cyclophosphamide 40 mg/kg IV on Day -5 and fludarabine 30 mg/m²/day IV from Day -5 to Day -2, followed by a single IV infusion of autologous bispecific CD20/CD19 CAR-T cells (XenCART; bicartigenlecleucel) at a dose of 2 × 10⁶ CAR-T cells/kg on Day 0. Dose may vary by ±20% due to manufacturing constraints.
Autologous bispecific CD20/CD19 CAR-T cells - 4 × 10⁶ cells/kgBiological
All patients receive lymphodepletion with cyclophosphamide 40 mg/kg IV on Day -5 and fludarabine 30 mg/m²/day IV from Day -5 to Day -2, followed by a single IV infusion of autologous bispecific CD20/CD19 CAR-T cells (XenCART; bicartigenlecleucel) at a dose of 4 × 10⁶ CAR-T cells/kg on Day 0. Dose may vary by ±20% due to manufacturing constraints.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLT)Time frame: Day 0 (infusion) to Day +28
- Incidence and maximum grade of cytokine release syndrome (CRS)Time frame: Day 0 to Day +28
- Incidence and maximum grade of ICANSTime frame: Day 0 to Day +28
- Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Day 0 to Month 24
- Maximum tolerated dose (MTD) / recommended Phase 2 dose (RP2D)Time frame: Day 0 to Day +28 of the last evaluable participant in each cohort
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Haematology A Block 5th Floor Ranipet Campus Kilminnal Village Christian Medical College Vellore Ranipet Campus
Vellore, Tamil Nadu, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.